Congenica was founded in 2014 as a Spin out from the Wellcome Sanger Institute, one of the leading genetic research institutions. The company’s platform, Sapientia, is a clinical genomic analytics platform that provides integration of human DNA sequences with deep clinical phenotyping, enabling clinicians and researchers to provide actionable interpretation of genetic disease for patients.
Congenica improves the opportunity for genomic characterization of disease. Supporting laboratories to achieve 30% higher analytical yields than averages and reduce analysis times and costs by 95%. This enables improvement of diagnostic confidence, maximize workflow efficiency and increase diagnostic yield and case throughput. It also supports rapid and accurate diagnoses and disease characterization, helping to provide patients with the treatment they need faster.
Genetic diseases occur in about 5% to 7% of newborns in Oman, which is significantly higher than the global average of 4.4%, with more than 300 types of inherited diseases in Oman. This is a large undertaking by the Ministry of Health, and an opportunity to introduce technologies to relieve the burden and reduce the cost of helping these patients.
In 2019, Congenica signed an agreement with the National Genetic Centre to aid in the management of Omani patients with rare genetic diseases.
IDO Value Add
With Congenica’s capabilities, there is vast potential for utilisation throughout advanced medical and genetic facilities in Oman and the wider GCC region. IDO Investments, together with Congenica and other regional partners are exploring opportunities to expand use, and are coordinating with relevant stakeholders to ensure benefit of this technology throughout Oman and beyond.
IDO Investments is also looking to use this partnership to aid Oman’s efforts in digitally streamlining the capture, processing and tracking of patient sample records.